CLDN18.2 inhibitor

DRUG CLASS:

CLDN18.2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1
CLDN18.2 positive + HER-2 negative	Gastric Cancer	CLDN18.2 positive + HER-2 negative	Gastric Cancer	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1
CLDN18.2 expression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B
CLDN18.2 expression + HER-2 negative	Gastric Cancer	CLDN18.2 expression + HER-2 negative	Gastric Cancer	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B
CLDN18.2 expression	Esophageal Adenocarcinoma	CLDN18.2 expression	Esophageal Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Gastric Adenocarcinoma	CLDN18.2 expression	Gastric Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 positive	Solid Tumor	CLDN18.2 positive	Solid Tumor	MIL93 Sensitive: C2 – Inclusion Criteria MIL93 Sensitive : C2	MIL93 Sensitive: C2 – Inclusion Criteria MIL93 Sensitive : C2
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AB011 Sensitive: C2 – Inclusion Criteria AB011 Sensitive : C2	AB011 Sensitive: C2 – Inclusion Criteria AB011 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Esophageal Cancer	CLDN18.2 expression	Esophageal Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 overexpression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 overexpression	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3
CLDN18.2 overexpression	Gastric Cancer	CLDN18.2 overexpression	Gastric Cancer	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	Q-1802 Sensitive: C3 – Early Trials Q-1802 Sensitive : C3	Q-1802 Sensitive: C3 – Early Trials Q-1802 Sensitive : C3
CLDN18.2 overexpression	Gastric Cancer	CLDN18.2 overexpression	Gastric Cancer	TST001 Sensitive: C3 – Early Trials TST001 Sensitive : C3	TST001 Sensitive: C3 – Early Trials TST001 Sensitive : C3
CLDN18.2 overexpression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 overexpression	Gastroesophageal Junction Adenocarcinoma	TST001 Sensitive: C3 – Early Trials TST001 Sensitive : C3	TST001 Sensitive: C3 – Early Trials TST001 Sensitive : C3
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AB011 Sensitive: C3 – Early Trials AB011 Sensitive : C3	AB011 Sensitive: C3 – Early Trials AB011 Sensitive : C3
CLDN18.2 positive	Pancreatic Cancer	CLDN18.2 positive	Pancreatic Cancer	ZL-1211 Sensitive: C3 – Early Trials ZL-1211 Sensitive : C3	ZL-1211 Sensitive: C3 – Early Trials ZL-1211 Sensitive : C3
CLDN18.2 positive	Gastric Adenocarcinoma	CLDN18.2 positive	Gastric Adenocarcinoma	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3
CLDN18.2 expression	Gastroesophageal Cancer	CLDN18.2 expression	Gastroesophageal Cancer	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3	TJ-CD4B Sensitive: C3 – Early Trials TJ-CD4B Sensitive : C3
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	ZL-1211 Sensitive: C4 – Case Studies ZL-1211 Sensitive : C4	ZL-1211 Sensitive: C4 – Case Studies ZL-1211 Sensitive : C4
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D	ZL-1211 Sensitive: D – Preclinical ZL-1211 Sensitive : D
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D	TJ-CD4B Sensitive: D – Preclinical TJ-CD4B Sensitive : D
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	nivolumab + TJ-CD4B Sensitive: D – Preclinical nivolumab + TJ-CD4B Sensitive : D	nivolumab + TJ-CD4B Sensitive: D – Preclinical nivolumab + TJ-CD4B Sensitive : D

CLDN18.2 inhibitor

CLDN18.2 inhibitor

Associations(30)

Associations
(30)